FDA
-
-
-
-
-
-
-
Lexaria extends pharmaceutical partnership agreement through April 2026
-
-
-
-
-
-
-
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
-
-
-
-
-
-
-
Lexaria claims technology could reduce GLP-1 drug side effects
-
-
-
-
-
-
-
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
-
-
-
-
-
-
-
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
-
-
-
-
-
-
-
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
-
-
-
-
-
-
-
Lexaria Bioscience (LEXX) Forms New Scientific Advisory Board
-
322,900 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

